M
Magdalena Zwierzyna
Researcher at University College London
Publications - 13
Citations - 365
Magdalena Zwierzyna is an academic researcher from University College London. The author has contributed to research in topics: Mendelian randomization & Drug development. The author has an hindex of 6, co-authored 11 publications receiving 157 citations. Previous affiliations of Magdalena Zwierzyna include British Heart Foundation & University of Bonn.
Papers
More filters
Journal ArticleDOI
Genetic drug target validation using Mendelian randomisation.
Amand F. Schmidt,Amand F. Schmidt,Chris Finan,María Gordillo-Marañón,Folkert W. Asselbergs,Folkert W. Asselbergs,Daniel F. Freitag,Riyaz S. Patel,Benoit Tyl,Sandesh Chopade,Rupert Faraway,Rupert Faraway,Magdalena Zwierzyna,Aroon D. Hingorani +13 more
TL;DR: A mathematical framework is introduced that contrasts MR analysis of proteins with that of risk factors located more distally in the causal chain from gene to disease, which has potential to aid drug development.
Journal ArticleDOI
Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005
TL;DR: Trial design and dissemination of results vary substantially depending on the type and size of funding institution as well as the disease area under study, ranging from 42% for autoimmune diseases to 20% for oncology.
Book ChapterDOI
Big Data in Drug Discovery
Nathan Brown,Jean Cambruzzi,Peter J Cox,Mark Davies,James Dunbar,Dean Plumbley,Matthew A Sellwood,Aaron Sim,Bryn Williams-Jones,Magdalena Zwierzyna,David W Sheppard +10 more
TL;DR: This work explains Big Data from the context of biology, chemistry and clinical trials, showcasing some of the impressive public domain sources and initiatives now available for interrogation.
Posted ContentDOI
Genetic drug target validation using Mendelian randomization
Amand F. Schmidt,Amand F. Schmidt,Chris Finan,María Gordillo-Marañón,Folkert W. Asselbergs,Folkert W. Asselbergs,Daniel F. Freitag,Riyaz S. Patel,Benoit Tyl,Sandesh Chopade,Rupert Faraway,Magdalena Zwierzyna,Aroon D. Hingorani +12 more
TL;DR: A formal mathematical framework is introduced that contrasts MR analysis of proteins with that of risk factors located more distally in the causal chain from gene to disease, and introduces an analytical framework for maximizing power and elucidating the robustness of drug target MR analyses.
Journal ArticleDOI
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Amand F. Schmidt,Amand F. Schmidt,Amand F. Schmidt,Nicholas B Hunt,María Gordillo-Marañón,María Gordillo-Marañón,Pimphen Charoen,Pimphen Charoen,Fotios Drenos,Fotios Drenos,Mika Kivimäki,Debbie A Lawlor,Claudia Giambartolomei,Olia Papacosta,Nishi Chaturvedi,Joshua C. Bis,Christopher J. O'Donnell,Christopher J. O'Donnell,Goya Wannamethee,Andrew Wong,Jacqueline F. Price,Alun D. Hughes,Alun D. Hughes,Tom R. Gaunt,Nora Franceschini,Dennis O. Mook-Kanamori,Magdalena Zwierzyna,Magdalena Zwierzyna,Reecha Sofat,Aroon D. Hingorani,Aroon D. Hingorani,Chris Finan +31 more
TL;DR: In this article, the authors compared evidence from clinical trials and drug target Mendelian randomization of cholesteryl ester transfer protein (CETP) protein concentration, and compared this to MendelIAN randomisation of proprotein convertase subtilisin/kexin type 9.